Evans WE - Search Results

1

Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion.

Relling MV, Stapleton FB, Ochs J, Jones DP, Meyer W, Wainer IW, Crom WR, McKay CP, Evans WE. Relling MV, et al. Among authors: evans we. Cancer. 1988 Sep 1;62(5):884-8. doi: 10.1002/1097-0142(19880901)62:5<884::aid-cncr2820620506>3.0.co;2-a. Cancer. 1988. PMID: 3261621

2

Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.

Rodman JH, Sunderland M, Kavanagh RL, Ochs J, Yalowich J, Evans WE, Rivera GK. Rodman JH, et al. Among authors: evans we. Cancer Res. 1990 Jul 15;50(14):4267-71. Cancer Res. 1990. PMID: 2194652 Clinical Trial.

3

Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.

Garré ML, Relling MV, Kalwinsky D, Dodge R, Crom WR, Abromowitch M, Pui CH, Evans WE. Garré ML, et al. Among authors: evans we. J Pediatr. 1987 Oct;111(4):606-12. doi: 10.1016/s0022-3476(87)80131-2. J Pediatr. 1987. PMID: 2958611

4

Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia.

Christensen ML, Rivera GK, Crom WR, Hancock ML, Evans WE. Christensen ML, et al. Among authors: evans we. J Clin Oncol. 1988 May;6(5):797-801. doi: 10.1200/JCO.1988.6.5.797. J Clin Oncol. 1988. PMID: 3163362

5

Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia.

Evans WE, Abromowitch M, Crom WR, Relling MV, Bowman WP, Pui CH, Ochs J, Dodge R. Evans WE, et al. NCI Monogr. 1987;(5):81-5. NCI Monogr. 1987. PMID: 3481040 Clinical Trial.

6

Patient characteristics associated with high-risk methotrexate concentrations and toxicity.

Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE. Relling MV, et al. Among authors: evans we. J Clin Oncol. 1994 Aug;12(8):1667-72. doi: 10.1200/JCO.1994.12.8.1667. J Clin Oncol. 1994. PMID: 8040679 Clinical Trial.

7

Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Evans WE, et al. Cancer Chemother Pharmacol. 1979;3(3):161-6. doi: 10.1007/BF00262416. Cancer Chemother Pharmacol. 1979. PMID: 316744 No abstract available.

8

Disposition of antineoplastic agents in the very young child.

McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, Rivera GK, Crist WM, Evans WE. McLeod HL, et al. Among authors: evans we. Br J Cancer Suppl. 1992 Aug;18:S23-9. Br J Cancer Suppl. 1992. PMID: 1503923 Free PMC article. Review.

9

Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.

Evans WE, Relling MV. Evans WE, et al. Pharmacogenetics. 1991 Dec;1(3):143-8. Pharmacogenetics. 1991. PMID: 1688245

10

Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.

Evans WE, Relling MV. Evans WE, et al. Mol Pharmacol. 1990 May;37(5):639-42. Mol Pharmacol. 1990. PMID: 1971090

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

633 results

Search Page

Filters